[go: up one dir, main page]

MA63498A1 - Formes posologiques orales d'ibrutinib - Google Patents

Formes posologiques orales d'ibrutinib

Info

Publication number
MA63498A1
MA63498A1 MA63498A MA63498A MA63498A1 MA 63498 A1 MA63498 A1 MA 63498A1 MA 63498 A MA63498 A MA 63498A MA 63498 A MA63498 A MA 63498A MA 63498 A1 MA63498 A1 MA 63498A1
Authority
MA
Morocco
Prior art keywords
ibrutinib
dosage forms
oral dosage
acidifying agent
cancers
Prior art date
Application number
MA63498A
Other languages
English (en)
Inventor
Mahmoud Ghannam
Shahin Fesharaki
Mohammad Al HREEBAT
Ahmad Arif MOHAMMAD
Original Assignee
Hikma Pharmaceuticals Usa Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hikma Pharmaceuticals Usa Inc. filed Critical Hikma Pharmaceuticals Usa Inc.
Publication of MA63498A1 publication Critical patent/MA63498A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formes posologiques orales stables et biodisponibles d'ibrutinib, les formes posologiques comprenant de l'ibrutinib et un agent acidifiant. Les formes posologiques peuvent en outre comprendre un liant, tel que de l'alginate de sodium, un tensioactif, un lubrifiant, une charge et/ou un délitant. L'invention concerne également des procédés de traitement de cancers, en particulier de cancers du sang, et la maladie du greffon contre l'hôte comprenant l'administration à un patient qui a besoin d'une forme posologique comprenant de l'ibrutinib et un agent acidifiant.
MA63498A 2021-06-10 2021-06-10 Formes posologiques orales d'ibrutinib MA63498A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/036712 WO2022260667A1 (fr) 2021-06-10 2021-06-10 Formes posologiques orales d'ibrutinib

Publications (1)

Publication Number Publication Date
MA63498A1 true MA63498A1 (fr) 2024-07-31

Family

ID=76731098

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63498A MA63498A1 (fr) 2021-06-10 2021-06-10 Formes posologiques orales d'ibrutinib

Country Status (3)

Country Link
MA (1) MA63498A1 (fr)
TN (1) TN2023000295A1 (fr)
WO (1) WO2022260667A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117064862B (zh) * 2023-04-10 2025-12-19 山东新时代药业有限公司 一种伊布替尼肠溶片及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087257A2 (fr) * 2010-12-20 2012-06-28 Mahmut Bilgic Forme galénique orale contenant de l'imatinib et production de ladite forme galénique orale
WO2016105582A1 (fr) * 2014-12-24 2016-06-30 Nunn Philip A Compositions pour administration de médicaments iléo-jéjunal.
WO2016141068A1 (fr) * 2015-03-03 2016-09-09 Pharmacyclics Llc Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton
WO2017174044A1 (fr) * 2016-04-06 2017-10-12 Zentiva, K.S. Formes solides d'ibrutinib
WO2018033941A2 (fr) * 2016-08-19 2018-02-22 Cipla Limited Compositions pharmaceutiques à base d'ibrutinib
CN111000806A (zh) * 2018-10-07 2020-04-14 威海云睿信息科技有限公司 一种依鲁替尼片剂组合物
US20200171036A1 (en) * 2015-04-06 2020-06-04 Janssen Pharmaceutica Nv Compositions Containing Ibrutinib
KR20200127888A (ko) * 2019-05-03 2020-11-11 보로노이 주식회사 이브루티닙 또는 이의 약학적으로 허용가능한 염을 포함하는 고형 제제 형태의 경구용 약학 조성물 및 이의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2585902T3 (es) 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
BR112014030424A8 (pt) 2012-06-04 2017-07-11 Pharmacyclics Inc Formas cristalinas de um inibidor de quinase de tirosina de bruton
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087257A2 (fr) * 2010-12-20 2012-06-28 Mahmut Bilgic Forme galénique orale contenant de l'imatinib et production de ladite forme galénique orale
WO2016105582A1 (fr) * 2014-12-24 2016-06-30 Nunn Philip A Compositions pour administration de médicaments iléo-jéjunal.
WO2016141068A1 (fr) * 2015-03-03 2016-09-09 Pharmacyclics Llc Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton
US20170258729A1 (en) * 2015-03-03 2017-09-14 Pharmacyclics Llc Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor
US20200171036A1 (en) * 2015-04-06 2020-06-04 Janssen Pharmaceutica Nv Compositions Containing Ibrutinib
WO2017174044A1 (fr) * 2016-04-06 2017-10-12 Zentiva, K.S. Formes solides d'ibrutinib
WO2018033941A2 (fr) * 2016-08-19 2018-02-22 Cipla Limited Compositions pharmaceutiques à base d'ibrutinib
CN111000806A (zh) * 2018-10-07 2020-04-14 威海云睿信息科技有限公司 一种依鲁替尼片剂组合物
KR20200127888A (ko) * 2019-05-03 2020-11-11 보로노이 주식회사 이브루티닙 또는 이의 약학적으로 허용가능한 염을 포함하는 고형 제제 형태의 경구용 약학 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
TN2023000295A1 (en) 2025-07-02
WO2022260667A1 (fr) 2022-12-15

Similar Documents

Publication Publication Date Title
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
ATE332138T1 (de) Flibanserin zur behandlung extrapyramidaler bewegungsstörungen
PA8588601A1 (es) Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
CY1117656T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
MY146351A (en) Compositions for treating infection in cattle and swine
EA200500782A1 (ru) Лечение геморрагического шока
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
NO20034863D0 (no) Deuterert 3-piperidinopropiofenon og medikamenter inneholdende disse
UY25544A1 (es) Forma de dosificación de nefazodona
JP2001510795A5 (fr)
MXPA04005420A (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1.
MA63498A1 (fr) Formes posologiques orales d'ibrutinib
BRPI0409935A (pt) composição para aperfeiçoar percepção e memória
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
NZ597657A (en) Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
Fitkalo et al. Clinical features of toxic jaw bone osteomyelitis in drug addicts
DE60014429D1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
Bao et al. Transposition of a lingual thyroid to the submandibular space using a modified technique
CO5170447A1 (es) Derivado de benzamida y medicamento que lo contiene
BRPI0410576A (pt) composto quìmico, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo de animal vivo